The Skin Microbiome in Graft Versus Host Disease

Status Recruiting

Clinical Trial Summary

Based on the evidence on the impact of the intestinal microbiome on the Graft Versus Host Disease (GVHD) after allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT), it is hypothesized that the skin-microbiome may play a role in cutaneous GVHD as well. Therefore, this study aims at investigating the skin-microbiota of patients with GVHD after allo-HSCT and of patients without GVHD after allo-HSCT.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04231500
Study type	Observational
Source	University Hospital, Basel, Switzerland
Contact	Simon Mueller, PD Dr. med
Phone	+41 61 328 69 64
Email	simon.mueller@usb.ch
Status	Recruiting
Phase
Start date	March 1, 2023
Completion date	March 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03357159` - Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation	Phase 2
Completed	`NCT00003270` - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer	Phase 2
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Recruiting	`NCT01385124` - Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation	Phase 1/Phase 2
Withdrawn	`NCT01616680` - Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease	Phase 2
Recruiting	`NCT01810926` - T&B Depletion Non Malignant	Phase 2
Completed	`NCT01379209` - Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)	Phase 1/Phase 2
Completed	`NCT01233921` - Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	N/A
Recruiting	`NCT00986557` - T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant	Phase 2
Enrolling by invitation	`NCT00972660` - Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease	Phase 2
Terminated	`NCT00555048` - Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer	Phase 1/Phase 2
Terminated	`NCT00373815` - Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease	Phase 1
Terminated	`NCT00608517` - Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil	N/A
Completed	`NCT00056875` - Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants	Phase 1/Phase 2
Recruiting	`NCT05808985` - Intestinal Microbiome-based Research for the Prevention of Acute GVHD	Phase 2
Completed	`NCT00813618` - Study of MEDI 507 in the Treatment of Pediatric Patients	Phase 1
Completed	`NCT00003398` - Bone Marrow Transplantation in Treating Patients With Hematologic Cancer	Phase 4
Terminated	`NCT00005641` - Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation	Phase 2
Completed	`NCT02663622` - Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)	Phase 2
Completed	`NCT00577278` - A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan	Phase 2